PROFESSIONAL EDITION

The largest community of pharma leaders

Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at Advisory Committee on Immunization Practices (ACIP) Meeting

CAMBRIDGE, Mass.–()–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced it is presenting at the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) August Meeting today. The live presentation can be viewed online here.

This presentation will include new interim safety and immunogenicity data from the cohorts of older adults in the NIH-led Phase 1 study of mRNA-1273, Moderna’s vaccine candidate against COVID-19. The ACIP presentation slides will be available under “Events and Presentations” in the Investors section of the Moderna website.

Conference Call and Webcast Information

Following the ACIP presentation of 10:30 ET, Moderna will host a live conference call and webcast at 4:30 p.m. ET on Wednesday, August 26, 2020. To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 2444108. A webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna’s website approximately two hours after the conference call.

Source

Recent Articles